PT - JOURNAL ARTICLE AU - KAZUMI HAGIWARA AU - TAKASHI TOKUNAGA AU - HIROATSU IIDA AU - HIROKAZU NAGAI TI - Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines AID - 10.21873/anticanres.13504 DP - 2019 Jul 01 TA - Anticancer Research PG - 3579--3584 VI - 39 IP - 7 4099 - http://ar.iiarjournals.org/content/39/7/3579.short 4100 - http://ar.iiarjournals.org/content/39/7/3579.full SO - Anticancer Res2019 Jul 01; 39 AB - Background/Aim: Neuroblastoma (NB) is the most common extracranial solid tumor in childhood; treatments with greater effectiveness are required for NB, especially in advanced cases. This study aimed at evaluating the combined effect of anaplastic lymphoma kinase (ALK) inhibitor alectinib and histone deacetylase inhibitor vorinostat on NB cell lines harboring wild-type or mutated ALK. Materials and Methods: Cytotoxicity was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide assay. Protein expression was analyzed using western blotting. Results: Combination treatment with alectinib and vorinostat had a synergistic effect on growth inhibition of the NB cell line with ALK R1275Q mutation. Cleavage of caspase-3 and poly-(ADP-ribose) polymerase increased, indicating enhanced caspase-dependent apoptosis. In addition, this combination reduced the protein levels of MYCN proto-oncogene and nuclear factor kappa B, both of which are important for NB tumorigenesis and progression. Conclusion: Combined treatment with alectinib and vorinostat might be a novel therapeutic option for NB harboring the ALK R1275Q mutation.